Kura Oncology announces first patient dosed in an investigator-sponsored phase 2 trial
Kura Oncology announced that the first patient has been dosed in an investigator-sponsored Phase 2 trial of its lead drug candidate, tipifarnib, an inhibitor of protein farnesylation, in cancer patients with urothelial carcinoma tumors characterized by HRAS mutations. November 30, 2015